Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832684 | 0.99 | KLK7 (0.52) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL29831604 | 0.95 | KLK7 (0.52) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL29942383 | 0.94 | KLK7 (0.49) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL29832010 | 0.93 | KLK7 (0.49) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL29832065 | 0.91 | MAPT (0.57) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL31060114 | 0.90 | CPB1 (0.53) | CPB1CPB2PSMB5 | |
| SCHEMBL29831718 | 0.89 | KLK7 (0.49) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL29831671 | 0.89 | CPB1 (0.50) | CPB1CPB2PSMB5 | |
| SCHEMBL29942304 | 0.86 | CPB1 (0.47) | CPB1CPB2PSMB5 | |
| SCHEMBL29831802 | 0.85 | CPB1 (0.46) | CPB1CPB2PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | disclosed |
| EP-4335452-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | KLK7 90/4885KLK5 397/4885MAPT 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.